$Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults$

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

<p>In this phase 4 study we assessed boosting with fractional doses of heterologous COVID-19 vaccines in Brazilian adults primed with two doses of CoronaVac (Sinovac/Butantan, São Paulo, Brazil) at least 4 months previously. Participants received either full-dose of ChAdOx1-S (Group...

Olles dieđut

Bibliográfalaš dieđut
Váldodahkkit:	Costa Clemens, SA, Marchevsky, N, Kelly, S, Felle, S, Eldawi, A, Rajasingam, R, Mahmud, R, Lambe, T, Voysey, M, Gonzalez, I, Milan, EP, Justino, MC, Bibi, S, Aley, P, Clemens, R, Pollard, AJ
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	Taylor and Francis 2023

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults

Geahča maid